Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia"
DOI: 10.1038/leu.2017.234
Abstract: Patients with advanced systemic mastocytosis (SM) (e.g. aggressive SM (ASM), SM with an associated hematologic neoplasm (SM-AHN) and mast cell leukemia (MCL)) have limited treatment options and exhibit reduced survival. Midostaurin is an oral multikinase… read more here.
Keywords: median follow; advanced systemic; systemic mastocytosis; patients advanced ... See more keywords
Delisting of Liver Transplant Candidates with Chronic HCV Infection after Viral Erradication: Outcome 2 Years after Delisting. A European Study
Sign Up to like & getrecommendations! Published in 2018 at "Transplantation"
DOI: 10.1097/01.tp.0000542536.91165.49
Abstract: European Liver and Intestine Transplant Association (ELITA). Background and Aims We showed in a previous ELITA study that second generation Direct Acting Antivirals (DAAs) can lead to a significant clinical improvement of patients listed for… read more here.
Keywords: delisted patients; outcome; median follow; two patients ... See more keywords
Updated Survival Analysis after a Median Follow-up of 12 Years of an Anthracycline-Containing Adjuvant Prospective Multicentre, Randomised Phase III Trial on Dose-Dense Chemotherapy in Primary Node-Positive, High-Risk Breast Cancer Patients
Sign Up to like & getrecommendations! Published in 2018 at "Breast Care"
DOI: 10.1159/000491792
Abstract: Purpose: Although dose-dense (dd) chemotherapy plays a fundamental role in the treatment of breast cancer (BC), a variety of trials have presented divergent survival results. Here, we present data of patients with more than 3… read more here.
Keywords: chemotherapy; median follow; follow years; dense chemotherapy ... See more keywords
Multicenter Phase II Trial Addressing Lenalidomide Maintenance in Patients with Relapsed Diffuse Large B-Cell Lymphoma (rDLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT): Efficacy and Safety Results after a Median Follow-up of Five Years
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-116060
Abstract: Background: Lenalidomide (LENA) maintenance is associated with significantly improved outcome in patients (pts) with chemosensitive relapse of DLBCL not eligible for ASCT or experiencing relapse after ASCT. Preliminary results of a multicentre phase II trial… read more here.
Keywords: trial; median follow; maintenance; toxicity ... See more keywords